Kevin P. McKian, Paul Haluska

Research output: Contribution to journalReview articlepeer-review

51 Scopus citations


The IGF pathway plays a major role in cancer cell proliferation, survival and resistance to antineoplastic therapies in many human malignancies. As such, interference with this pathway is the target of many investigational pharmacologic agents. Cixutumumab, a monoclonal antibody to IGF-1R, utilizes this concept. In this review, we summarize preclinical, pharmacologic and early clinical data regarding this agent and discuss the impact this drug might have on the future treatment of human cancers.

Original languageEnglish (US)
Pages (from-to)1025-1033
Number of pages9
JournalExpert Opinion on Investigational Drugs
Issue number7
StatePublished - Jul 2009


  • Cixutumumab
  • IGF-1R
  • IMC-A12
  • Monoclonal antibody

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Cixutumumab'. Together they form a unique fingerprint.

Cite this